Ask AI

Evolving Landscape in Curative-Intent Treatment for HNSCC

Text Module
Text Module Start Activity
This activity is available for 0.25 CME/CE credit(s).

Released: August 17, 2026

Expiration: February 16, 2027

See Activity Collection

Review this text module to learn about current therapeutic strategies and treatment options being explored in clinical trials for locally advanced head and neck cancer.

Curative Intent Treatment for HNSCC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with head and neck squamous cell carcinoma (HNSCC) do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

In the phase III KEYNOTE-689 trial in patients with LA-HNSCC, for which population of patients was there an event-free survival (EFS) benefit with the addition of perioperative pembrolizumab to standard of care (SoC) surgery plus adjuvant radiotherapy with or without cisplatin?

4.

In the phase III NANORAY-312 trial of NBTXR3 plus radiotherapy, which feature most directly addresses an unmet need in LA-HNSCC?